QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer
ConditionAdvance Pancreatic Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorDu Juan
About this trial
The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 80 patients with advanced pancreatic cancer who have not received prior treatment. This study aims to enhance the anti-tumor immune effect through the combination of QL1706+Lenvatinib+AG regimen, thereby improving the prognosis of patients with advanced metastatic pancreatic cancer.
Eligibility criteria
Qualifiers
a. Age ≥18 years, ECOG performance status ≤2, and expected survival of ≥3 months.
b. Patients with histologically or cytologically confirmed advanced metastatic pancreatic cancer.
c. At least one measurable lesion according to RECIST 1.1 criteria;
d. No prior anti-tumor treatment of any kind.
Disqualifiers
a. Prior receipt of systemic anti-tumor treatment, such as chemotherapy, radiotherapy, or other anti-tumor treatments.
b. Participation in another drug clinical trial within the past 4 weeks.
c. Subjects who, in the investigator's judgment, have the opportunity for surgery or are potentially operable (subjects who voluntarily forgo surgical treatment may be enrolled after investigator assessment and agreement).
d. Subjects with moderate ascites requiring drainage (except for those with minimal ascites shown on imaging without symptoms).
Trial design
Treatments tested in this trial
- QL1706+Lenvatinib+AG Regimen
Treatment groups
80 Participants
are divided into 1 treatment groupSponsors and collaborators
Du Juan
Lead sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Sponsor institution
Source ClinicalTrials.gov